Zydus Cadila has received the final approval from the USFDA to market Ranolazine Extended Release Tablets (US RLD - Ranexa®), 500 mg and 1.000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group's formulations manufacturing facility at Baddi.
The group now has 271 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.219.9 as compared to the previous close of Rs. 218.65. The total number of shares traded during the day was 43779 in over 808 trades.
The stock hit an intraday high of Rs. 220 and intraday low of 214.55. The net turnover during the day was Rs. 9555100.